177Lu-PSMA-617
Drug timelines are a Plus or Pro feature.
18 regulatory and trial events tracked for 177Lu-PSMA-617, covering 2021-08-24 to 2026-06-08. Get the full timeline:
Most recent: Clinical Trial Update: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]